The latest edition of the mhGAP guideline aims to help countries improve their ability to address mental, neurological and substance use (MNS) conditions and reduce the treatment gap. With 30 updated and 18 new recommendations, in addition to the 90 pre-existing ones, this third iteration of the guideline reflects years of investment in the mhGAP programme. The need for improved capacity to address MNS conditions is growing, and the mhGAP guideline is designed to assist countries in meeting this challenge.
The revised recommendations are intended to ensure that mhGAP provides non-specialist health workers in low and middle-income countries with high-quality, timely, transparent, and evidence-based guidance to effectively treat and care for individuals with MNS conditions. This edition includes 30 updated recommendations and 18 new ones, which are focused on narrowing the treatment gap.
The development of this latest edition represents significant investment in the mhGAP programme over the past 15 years. The goal is to ensure that non-specialist health workers have access to evidence-based guidance on how to diagnose and treat MNS conditions. This will ultimately lead to better health outcomes for individuals living with these conditions in low and middle-income countries.